on MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals Advances Ketamir-2 Trial for Neuropathic Pain
MIRA Pharmaceuticals, Inc. has announced the enrollment of the first subjects in its Phase 1 clinical trial for Ketamir-2, an innovative oral ketamine analog aimed at treating neuropathic pain. Taking place at Hadassah Medical Center in Jerusalem, the trial involves 56 participants across Single and Multiple Ascending Dose cohorts. This study will explore the safety and effectiveness of Ketamir-2.
Ketamir-2 has shown promising preclinical results, outperforming existing treatments like pregabalin and gabapentin and maintaining a favorable safety profile without the side effects typical of ketamine. MIRA plans to conclude Phase 1 by Q4 2025 and initiate a Phase 2a trial by the year-end for diabetic neuropathic pain.
Additionally, MIRA's acquisition of SKNY Pharmaceuticals is set to enhance their pipeline, supporting the development of SKNY-1, an oral therapeutic for weight loss. This acquisition reflects MIRA's commitment to diversifying its treatment options for chronic conditions.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MIRA Pharmaceuticals news